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developed based on a systematic high-throughput screening 
campaign combined with medicinal chemistry optimiza-
tion. In vitro, anle138b blocked the formation of pathologi-
cal aggregates of prion protein (PrPSc) and of α-synuclein  
(α-syn), which is deposited in PD and other synucleinopa-
thies such as dementia with Lewy bodies (DLB) and mul-
tiple system atrophy (MSA). Notably, anle138b strongly 
inhibited all prion strains tested including BSE-derived and 
human prions. Anle138b showed structure-dependent bind-
ing to pathological aggregates and strongly inhibited forma-
tion of pathological oligomers in vitro and in vivo both for 
prion protein and α-synuclein. Both in mouse models of prion 
disease and in three different PD mouse models, anle138b 
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strongly inhibited oligomer accumulation, neuronal degen-
eration, and disease progression in vivo. Anle138b had no 
detectable toxicity at therapeutic doses and an excellent oral 
bioavailability and blood–brain-barrier penetration. Our 
findings indicate that oligomer modulators provide a new 
approach for disease-modifying therapy in these diseases, 
for which only symptomatic treatment is available so far. 
Moreover, our findings suggest that pathological oligom-
ers in neurodegenerative diseases share structural features, 
although the main protein component is disease-specific, 
indicating that compounds such as anle138b that modu-
late oligomer formation by targeting structure-dependent 
epitopes can have a broad spectrum of activity in the treat-
ment of different protein aggregation diseases.
Introduction
As life expectancy continues to rise, the increasing preva-
lence of age-related neurodegenerative diseases poses major 
problems to public health. For example, PD affects about 
1 % of people beyond 65 years of age [19]. Pathologically, 
PD is characterized by deposition of α-synuclein (α-syn) 
aggregates and degeneration of dopaminergic neurons in 
the substantia nigra resulting in impaired motor functions. 
A crucial role of α-syn aggregates in disease pathogenesis 
is suggested by abundant evidence including (1) the consist-
ent detection of α-syn deposits in affected brain areas, (2) 
pathogenic mutations affecting the α-syn gene in familial 
PD and association of the α-syn locus with idiopathic PD in 
genome-wide association studies, and (3) experimental evi-
dence in vitro, in cell culture, and in animal models [34, 57].
Several studies indicate that α-synucleinopathies as well 
as other protein aggregation diseases share key molecular 
features [29, 58] including aggregate toxicity and spread 
by seeded aggregation with prion disorders [1, 31]. Prion 
diseases are invariably fatal neurodegenerative diseases that 
include Creutzfeldt-Jakob disease (CJD) and bovine spongi-
form encephalopathy (BSE). They are caused by an uncon-
ventional infectious agent which consists primarily of the 
misfolded, aggregated, beta-sheet rich PrPSc isoform of the 
membrane glycoprotein PrPC [51]. The available evidence 
suggests that PrPSc acts both as a template for this conver-
sion and as a neurotoxic agent causing neuronal dysfunction 
and cell death [13, 51].
Recent evidence indicates that pathological oligomers [7] 
rather than large fibrillar deposits constitute the key neuro-
toxic species [4, 22, 35]. Thus, we set out to discover small 
molecules targeting pathological oligomers to provide a 
therapeutic strategy for causal disease-modifying treatment 
of these devastating diseases and other protein aggregation 
disorders for which only symptomatic treatment is available 
so far [20, 22, 59].
Materials and methods
Screening for anti-prion compounds
Compound libraries
The two libraries screened contain 10,000 compounds each 
and are called DIVERSet1 and DIVERSet2, because they 
cover only a part of the larger DIVERSet library (Chem-
Bridge Corp., San Diego, CA). DIVERSet is a collection of 
rationally selected, diverse, drug-like small molecules. The 
compounds were supplied in dimethyl sulfoxide (DMSO) 
solution on 96-well microtiter plates. A database containing 
molecular structures and some physico-chemical data for 
each of the compounds is available at www.chembridge.com. 
Based on the discovery of the new di-phenyl-pyrazole 
(DPP) lead structure (Fig. 1), a focussed compound library 
was generated. Details regarding synthesis and quality con-
trol of >150 newly synthesized DPP-related compounds are 
provided in the Supplement “Compound Synthesis”. Unless 
otherwise noted, materials and solvents were purchased 
from commercial sources (Sigma-Aldrich, Germany; Alfa 
Aesar, Germany) and used without purification.
Assay for PrPC–PrPSc association by scanning for 
intensely fluorescent targets (SIFT)
Recombinant PrP 23-231 (rPrP) was produced and puri-
fied essentially as described [2]. L42 monoclonal anti-
body (r-biopharm, Darmstadt, Germany) was labelled with 
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Alexa-Fluor-647 (Invitrogen, Eugene) according to the 
manufacturer’s manual. Recombinant mouse PrP 23-231 
was labelled with Alexa-Fluor-488 (Invitrogen, Eugene) in 
20 mM potassium phosphate buffer, pH 6, 0.1 % Nonidet P40, 
40 mM sodium bicarbonate buffer, pH 8.3. Unbound fluoro-
phores were separated by gel filtration on PD10 columns (GE 
Healthcare, Freiburg, Germany) equilibrated with 20 mM 
potassium phosphate buffer, pH 6, 0.1 % Nonidet P40. PrPSc 
was prepared from brain of CJD patients according to Safar 
et al. [54] and aliquots of the final pellet resuspended in 1× 
PBS + 0.1 % sarcosyl solution were diluted 1:5 into buffer A 
(20 mM potassium phosphate buffer at pH 6.0, 0.1 % Nonidet 
P40) and sonicated in a water-bath sonicator for 60 s. After 
centrifugation at 1,000 rpm for 1 min the supernatant was 
Fig. 1  Summary of experimental strategy. In a first project phase, we 
tested a library of 10,000 chemically diverse drug-like compounds 
in regard to inhibition of prion protein aggregation in a molecular 
SIFT screening assay. Based on this data in combination with test-
ing of primary hits in a cellular anti-prion assay, we identified N-ben-
zylidene-benzohydrazide (NBB) derivatives as a new lead structure 
with anti-prion activity providing a proof of principle of the experi-
mental strategy. Notably, the same compounds also inhibit Poly-Q 
and α-syn aggregation both in vitro and in vivo. However, NBB’s 
contain a Schiff’s base like =N–NH–CO– structure that can result 
in rapid metabolism in vivo. In order to identify further lead struc-
tures with favourable medicinal chemical properties, we continued by 
screening of 10,000 additional compounds and performed a parallel 
analysis of all these 20,000 compounds in a microtiter plate based 
high-throughput anti-prion cell culture assay followed by structure–
activity and cluster analysis of the data obtained with these two inde-
pendent approaches (Suppl. Fig. 1). This analysis identified a cluster 
of highly active compounds belonging to the chemical compound 
class of 3,5-diphenyl-pyrazole (DPP) derivatives. A pilot experiment 
with one DPP compound from the initial screening library showed a 
significant effect on survival in prion-infected mice (Suppl. Fig. 2). 
Therefore, we synthesized a focused library of ~150 DPP-related 
compounds (Suppl. “Compound Synthesis”) for further testing in 
vitro, in cell culture, and in vivo in regard to therapeutic effects on 
prion and α-syn aggregation and disease progression in animal mod-
els. Based on results from the SIFT and cell culture anti-prion assays, 
38 compounds were selected for in vivo testing in prion-infected 
mice (Suppl. Fig. 3). In these experiments, the compound anle138b 
[3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole] showed 
the highest anti-prion activity. In addition, anle138b showed efficacy 
in in vitro and in vivo models for synucleinopathies such as PD
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diluted 1:100 in buffer A for the assay. A mixture of labelled 
mouse rPrP and labelled L42 monoclonal antibody was pre-
pared in buffer A so that the labelled molecules were approx-
imately equally abundant at 2–6 nM. In a 20-μl assay vol-
ume 8 μl of the rPrP/antibody mixture, 2 μl compound (final 
concentration in primary screening: 10 μM), and 10 μl of 
the diluted PrPSc preparation were mixed. The samples were 
loaded onto 96-well plates with cover-glass bottom (Evotec-
Technologies, Hamburg, Germany) and measured using dual-
colour SIFT on an Insight Reader as described [2].
Inhibition of PrPSc accumulation in a cell‑based dot blot 
assay
Mouse neuroblastoma (ScN2a) and scrapie mouse brain 
(SMB) cells (TSE Resource Centre) [6], infected with the 
Rocky Mountain Laboratory (RML) scrapie strain, were 
seeded in a concentration of 20,000 cells per well in 100 μl 
of medium at a Costar 3599 flat-bottom 96-well plate (Corn-
ing Inc., Corning, NY) prior to compound addition. Test 
compounds were added to the cell medium in a final dilution 
of 20 and 2 μM, respectively. After an incubation period of 
3 days at 37 °C (ScN2a cells) or at 35 °C (SMB cells) in 
a CO2 incubator the cultures were lysed and analyzed for 
PrPSc formation.
After cell medium removal, 100 μl of lysis buffer 
(50 mM Tris/HCl, ph 8.0, 150 mM NaCl; 0.5 % (w/v) DOC; 
0.5 % (v/v) Triton X-100) was added to each well for 5 min 
at room temperature. Using a dot blot apparatus (Sigma-
Aldrich) cell lysate was transferred under vacuum to an acti-
vated polyvinylidene difluoride (PVDF) membrane (Immo-
bilon-P; Milipore) and fixed to the membrane by incubation 
for 1 h at 37 °C. The membrane was incubated in lysis buffer 
and treated with proteinase K solution (final dilution 25 μg/
ml) for 90 min at 37 °C. Subsequently, the membrane was 
washed twice with pure water, the denaturation solution 
(3 M Guanidiniumthiocyanat, 0.1 M TrisHCl pH 8.0) was 
added for 15 min at room temperature and membranes were 
washed five times with pure water. After the denaturation 
step the membrane was blocked with PBST-milk [5 % (w/v) 
non-fat milk, 0.1 % (v/v) tween-20 (Sigma) in phosphate 
buffered saline (PBS)] for 60 min. An appropriate dilution 
of polyclonal antibody “rabbit-10” [30] in PBST-milk was 
incubated with the membrane for 60 min. After PBST rins-
ing, the membrane was incubated in a 0.2-μg/ml concentra-
tion of Horseradish Peroxidase (HRP) conjugated, anti-rab-
bit IgG antibody (Promega) in PBST-milk for 1 h at room 
temperature. After additional PBST rinsing the bound anti-
bodies were detected using a chemiluminescence reagent 
system (ECL, Amersham) and were visualized directly in an 
image analysis system (Versa Doc, Quantity One, Bio-Rad, 
Munich, Germany). Inhibition was calculated as relative 
signal volume compared to the untreated control (100 %).
Experiments in prion-infected mice
Inoculation with RML prions and therapeutic treatment
For screening and structure–activity analysis, compounds 
were tested in regard to their inhibitory effect on PrPSc accu-
mulation in vivo by three experimental protocols:
a) Seven-week-old female C57BL/6 mice were inocu-
lated intracerebrally (i.c.) with 30 μl of 1 % (w/v) brain 
homogenate (RML scrapie). Treatment was started at 
80 days post infection (dpi) with 1 mg compound per 
day mixed with 10 μl DMSO + 200 μl peanut butter 
applied orally. PrPSc level in brain was measured at 
120 dpi by immunoblot analysis.
b) Seven-week-old female C57BL/6 mice were inocu-
lated intraperitoneally (i.p.) with 100 μl of 1 % (w/v) 
brain homogenate (RML scrapie). PrPSc level in the 
spleen was determined at 35 dpi following 34 days 
of treatment with 1 mg compound mixed with 10 μl 
DMSO + 200 μl peanut butter per day.
c) Seven-week-old female C57BL/6 mice were inocu-
lated i.c. with 30 μl of 1 % (w/v) brain homogenate 
(RML scrapie). Treatment was started at 80 dpi with 
0.84 mg compound (in 25 μl DMSO) per day applied 
by intraperitoneal injection for 14 days followed by 
2 × 5 days (with 2 days without treatment in between) 
of 1 mg compound (in 10 μl DMSO + 40 μl vegetable 
oil) applied orally by gavage. PrPSc level in brain was 
measured at 106 dpi.
For long-term survival experiments, anle138b was 
administered orally in DMSO/peanut butter as described 
above. In a first set of experiments, 5 mg anle138b were 
given once daily starting either at day 80 or day 120 post 
i.c. infection. Animals of each treatment group were moni-
tored daily for signs of disease by trained animal caretakers 
from day 80 post infection. The animals were sacrificed, 
when they had reached the terminal stage of the disease 
based on clinical signs (ataxia, tremor, difficulty in right-
ing up from a position lying on its back and tail stiffness). 
Typically the disease progress through the terminal stage 
will lead to the death of the animal within 1 or 2 days. 
In addition, groups of four mice per experimental group 
were sacrificed at predefined time points as indicated in 
Fig. 3c–e. From all animals, one brain hemisphere and one 
half of the spleen were freshly frozen at −80 °C for bio-
chemical analysis. The other hemisphere and the remain-
ing half of the spleen as well as all inner organs were fixed 
in 4 % formaldehyde solution for histological analysis. In 
a further experiment, treatment with anle138b was started 
on the day of i.c. infection with a dose of 5 mg anle138b 
twice daily.
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Histology and immunohistochemistry
Prion infectivity was inactivated by immersion in 100 % 
formic acid [8]. Paraffin-fixed sections (2.5 μm) of brain 
tissue were stained with H&E. For PrPSc detection using 
antibody CDC1 [50], sections were immunostained on a 
Ventana automated staining apparatus. To assess neuronal 
degeneration, neurons with pyknotic nuclei were counted 
in blinded slides in the cerebellar granule cell layer. This 
approach has been validated previously as an efficient 
measure for apoptotic neuronal cell death [28]. For each 
animal, 30 randomly chosen high power visual fields were 
analyzed.
Quantification of PrPSc
For quantification of PrPSc, brain homogenates were 
homogenized 10 % (w/v) in lysis buffer (100 mM NaCl, 
10 mM EDTA, 0.5 % (v/v) NP-40, 0.5 % (w/v) deoxy-
cholate, 10 mM Tris/HCl pH 7.4) and subjected to dot 
blot analysis using 6H4 antibody (Prionics, Switzer-
land) at a dilution of 1:5,000. For PrPSc immunoblotting, 
infected brain homogenates were treated with protein-
ase K (100 μg/ml, 1 h, 37 °C) prior to dot blot analysis. 
Spleens were homogenized in Dulbecco’s PBS 10 % (w/v) 
and PrPSc was precipitated from 500 μl of homogenates 
using sodium phosphotungstic acid (NaPTA) as previously 
described [65]. Pellets were resuspended in 20 μl of 0.1 % 
sarkosyl buffer and treated with proteinase K (50 μg/ml, 
1 h, 37 °C). PrP was visualized with CDP-Star detection 
reagent (Roche, Mannheim, Germany). Quantification was 
performed using a Diana III luminescence imaging system 
along with the AIDA software package (Raytest, Strauben-
hardt, Germany). The relative inhibition of PrPSc accumula-
tion compared to DMSO-treated groups was calculated as 
follows:
where x amount of PrPSc in compound-treated group at end 
of treatment period, s amount of PrPSc in control group at 
start of treatment period, and c amount of PrPSc in control 
group at end of treatment period.
Protein misfolding cyclic amplification (PMCA) [5, 53]
Frozen BSE- and scrapie-infected mouse brains and human 
sporadic CJD (sCJD) and variant CJD (vCJD) brain samples 
were homogenized in cold PMCA conversion buffer, con-
taining 1-fold PBS, 1 % Triton X-100, 5 mM EDTA, 150 mM 
NaCl and protease inhibitor cocktail tablets (Roche, Basel, 
Switzerland). Crude 10 % (w/v) homogenates were centri-
fuged for 10 s at 2,000×g. Aliquots of the supernatant were 
immediately frozen at −80 °C for subsequent experiments. 
% Inhibition = (1 − (x − s) / (c − s)) × 100
Whole normal mouse brains were obtained from 10-week-
old C57BL/6 mice. After homogenization in cold PMCA 
conversion buffer, 10 % (w/v) normal brain homogenates 
were centrifuged for 10 s at 2,000×g, and aliquots of the 
supernatant were frozen at −80 °C. Frozen cortex from non-
CJD human brain was homogenized as above.
PMCA was performed in a water-bath sonicator (Misonix 
sonicator 3000, Misonix, Farmingdale, NY, USA), which 
had a microplate horn for PCR tubes. Normal brain homoge-
nate was mixed with infected brain homogenate (100:1 v/v) 
and 99 μl of this mixture was transferred into 0.2-ml PCR 
tubes which contained 1 μl of DMSO or compound solved 
in DMSO. For mouse substrates 18 PMCA cycles and for 
human substrates 40 cycles were performed. Each cycle 
consisted of sonication at 60 % potency (~209 W) for 20 s 
followed by incubation at 37 °C for 59 min 40 s.
PMCA product was digested with 50 μg/ml proteinase 
K at 37 °C for 1 h. After adding an equal volume of SDS 
loading buffer and boiling for 10 min, samples were sepa-
rated by SDS-PAGE and transferred to PVDF membranes 
(Immobilon-P, Millipore, MA, USA) at 12 V for 2 h. For 
immunoblotting, the membrane was blocked with 5 % non-
fat milk in PBST and incubated with 1:5,000 diluted PrP 
monoclonal antibody 3F4 (Dako, Glostrup, Denmark) in 
PBST at room temperature for 2 h. After three washes in 
PBST, the membrane was immerged in a 1:5,000 diluted 
alkaline phosphatase conjugated anti-mouse IgG (Dako) in 
PBST and incubated at room temperature for 2 h. Detec-
tion was performed with CDP-Star solution (Roche, 
Mannheim, Germany). Immunoblots were scanned and 
quantified by a Diana III luminescence imaging system along 
with the AIDA software package (Raytest, Straubenhardt, 
Germany). In the Western blots shown in Fig. 4c, d “start” 
indicates the sample taken from the PMCA reaction mixture 
at time point 0 after mixing normal brain homogenate with a 
minute amount of PrPSc that acts as a seed for the subsequent 
PMCA reaction. Thus, this sample provides the reference 
for samples “anle234b”, “anle138b” and “DMSO”, which 
following PMCA incubation contain different amounts of 
newly formed PK-resistant PrPSc depending on the differ-
ent efficacy of prion amplification during PMCA. Thus, this 
assay design (comparison of time points before and after 
PMCA amplification) does not require a “loading control”.
α-Synuclein in vitro oligomer formation assay
Expression and purification of recombinant wild-type 
α-synuclein (α-syn) was performed according to established 
protocols [38]. Fluorescent labelling of α-syn and quality 
control were performed as described [27]. For α-syn aggre-
gation experiments, a 5-fold stock solution of fluorescently 
labelled α-syn was prepared by mixing α-syn labelled 
with Alexa-488 and α-syn labelled with Alexa-647. The 
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concentrations of α-syn-Alexa-488 and α-syn-Alexa-647 
were adjusted to ~10 molecules/focal volume and ~15 mol-
ecules/focal volume, respectively.
The α-syn aggregation assay was conducted with minor 
modifications as published previously [38]. All experiments 
were performed in 50 mM Tris-buffer (pH 7.0) in a total 
volume of 20 μl in 384- or 96-well plates with a cover slide 
bottom (Evotec-Technologies, Germany). The concentra-
tion of α-syn was approximately 20 nM. In all experiments, 
α-syn aggregation was induced by final concentrations of 
1 % DMSO and 10 μM FeCl3. Compounds were diluted 
into the assay mixture from 10-fold stock solutions contain-
ing 10 % DMSO (v/v), resulting in a final concentration of 
1 % DMSO in all samples. “Low control” measurements for 
threshold setting were obtained without FeCl3 and DMSO. 
Experiments were started by diluting the 5-fold stock solu-
tion of fluorescently labelled α-syn in 50 mM Tris-buffer, 
pH 7.0, containing 1 % DMSO, 10 μM FeCl3 and com-
pounds in concentrations ranging from 1–10 μM. Aggrega-
tion was monitored at room temperature for at least 2.5 h in 
3–4 independent samples for each experimental group.
Aggregation of α-syn was measured by scanning for 
intensely fluorescent targets (SIFT) [3]. SIFT measurements 
were carried out on an Insight Reader (Evotec-Technolo-
gies) with dual-colour excitation at 488 and 633 nm, using a 
40 × 1.2 numerical aperture microscope objective (Olympus, 
Japan) and a pinhole diameter of 70 μm at FIDA setting. Exci-
tation power was 200 μW at 488 nm and 300 μW at 633 nm. 
Measurement time was 10 s. Scanning parameters were set 
to 100 μm scan path length, 50 Hz beam scanner frequency, 
and 2,000 μm positioning table movement. The frequency 
of specific combinations of “green” and “red” photon counts 
was recorded in a two-dimensional intensity distribution his-
togram, as described previously [27]. Evaluation of SIFT data 
in two-dimensional intensity distribution histograms was per-
formed by summing up the numbers of photons from high 
intensity bins using a two-dimensional SIFT software module 
(Evotec-Technologies). For threshold setting, non-aggregated 
reference samples were used. The photon count in bins above 
the threshold was considered aggregate signal.
α-syn oligomer pore formation in planar lipid bilayers
Planar lipid bilayers were generated and analyzed in a Ionova-
tion Compact (Ionovation, Osnabrück, Germany) by the paint-
ing technique [46]. Two bath chambers (1.2 ml) separated by a 
Teflon-septum were filled with 250 mM KCl, 10 mM MOPS, 
pH = 7.2 (Merck, Darmstadt, Germany and Roth, Karlsruhe, 
Germany). Then, 2 μl of a 100 mg/ml-solution of purified 
azolectin in n-Decan (Ionovation, Osnabrück, Germany) were 
applied to a 120-μm pinhole in the septum. After 30 min incu-
bation at room temperature, lipid was thinned out by repeti-
tive lowering and re-raising of the buffer level until a bilayer 
was formed. This formation was monitored optically and by 
capacitance measurements. The resulting bilayers had a typi-
cal capacitance of 60–80 pF and a resistance of >100 GΩ. 
Measurements were performed using Ag/AgCl-electrodes 
connected to an EPC10-amplifier and Patchmaster software 
(HEKA, Lambrecht/Pfalz, Germany). The noise was ~0.5 pA 
at 3 kHz bandwidth. α-syn was incubated in 50 mM Tris–
HCl, pH 7.0 with 1 % DMSO (Sigma-Aldrich, Taufkirchen, 
Germany) and 20 μM FeCl3 (Merck, Darmstadt, Germany) 
for 72 h at room temperature in a total volume of 200 μl. Con-
centration of alpha-synuclein was 2.1 μM. Compounds were 
added at the start of incubation in concentrations of 50 μM 
(baicalein) or 25 μM (anle138b). After bilayer formation, α-
syn was added in 20 μl aliquots to the cis chamber close to the 
membrane and the electrophysiological properties were moni-
tored. Threshold for pore detection was set to 72 pS. If no pore 
formation was detected for 5 min, the next aliquot of the same 
sample was added as described previously [55].
Oral rotenone in vivo mouse model of Parkinson’s disease
One-year old C57Bl/6J mice were maintained in a constant 
light/dark cycle (12 h/12 h). Water and food were given 
ad libitum. Mice were divided into 4 groups (“no rote-
none”, “rotenone/normal feed”, “rotenone/placebo feed”, 
“rotenone/anle138b”). A further group of mice (“rotenone/ 
hemivagotomy”) that was used for comparison was hemiva-
gotomized previous to rotenone treatment as previously 
described [49]. This procedure partially prevents the spread 
of pathology from the enteric nervous system to the CNS 
resulting in a decreased dopaminergic cell death. Oral rote-
none treatment was performed as previously described [48]. 
Briefly, mice were treated with 0.01 ml/g body weight of solu-
tions containing either only vehicle [4 % carboxymethylcellu-
lose (Sigma-Aldrich, Germany) and 1.25 % chloroform (Carl 
Roth, Germany)] or rotenone (0.625 mg/ml rotenone (Sigma-
Aldrich, Germany), 4 % carboxymethylcellulose and 1.25 % 
chloroform) once a day, 6 days/week for 4 months. Treatment 
was administered orally with the help of a 1.2 × 60-mm gav-
age (Unimed, Switzerland). During treatment, two groups of 
rotenone-treated mice were supplied with the same batch of 
food pellets (Ssniff, Soest, Germany) that either contained 
the compound (“rotenone/anle138b” group) or were pre-
pared without anle138b (“rotenone/placebo feed” group). 
The other two groups (“no rotenone” and “rotenone/normal 
feed”) were fed with standard food pellets. The locomotor 
abilities of the mice were tested using an acceleration proto-
col of the rotarod test, as previously described [48]. The test 
was repeated once a month, four times a day on each animal 
over three consecutive days. In addition, a 1-h stool collec-
tion test was performed on 4 consecutive days once a month 
as previously described [49] to assess gut motility and func-
tion of the enteric nervous system. All animal experiments 
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were carried out in accordance with the National Institutes 
of Health Guide for the Care and Use of Laboratory Animals 
that had been approved by the Saxonian Committee for Ani-
mal Research, Dresden, Germany.
Transgenic α-synuclein mouse model
The in vivo effect of anle138b was tested in a well-
established murine α-synucleinopathy model {(Thy1)-
h[A30P]α-syn} on a genetic background of C57/Bl6 mice 
[47]. Anle138b treatment was tested against placebo treat-
ment with the vehicle (DMSO/peanut butter). Further-
more, untreated non-transgenic C57/Bl6 mice were exam-
ined as age-matched controls. The animals were evaluated 
clinically regarding survival time, motor performance and 
body weight. In addition, we conducted histological post 
mortem evaluation of α-syn deposition. Treatment with 
anle138b and placebo, respectively, was initiated at the age 
of 8 weeks. Transgenic animals in the treatment and pla-
cebo group were matched both in regard to litter and sex. 
Anle138b was solved in DMSO and mixed with peanut but-
ter. Five days prior to the first dose of anle138b, initial doses 
of 200 μl peanut butter (Barney′s best creamy peanut but-
ter, Dockhorn & Co, Hamburg, Germany) were given to the 
mice once daily. During the first 2 weeks of treatment, 2 mg 
of anle138b dissolved in 10 μl DMSO mixed with 200 μl 
peanut butter were given. After 2 weeks of treatment, the 
dose was increased to 5 mg in 10 μl DMSO/200 μl peanut 
butter. At the age of 33 weeks, the dose was increased to 
2 × 5 mg per day. All mice were monitored daily for signs 
of disease. Detailed clinical assessment including behaviour 
and movement was performed once a week. Every 2 weeks, 
rotarod performance and body weight was monitored.
For assessment of motor performance, a Rotarod advanced 
for five mice V4.1.1 (TSE Systems, Chesterfield, MO, USA) 
was used. All mice were tested regarding their rotarod perfor-
mance every 2 weeks beginning with an age of 250–260 days. 
On the 2 days prior to the rotarod performance test, mice were 
trained in three trial runs each during which the rotarod accel-
erated from 0 to 30 rpm over a period of 180 s. On the third 
day, the test consisted of three runs on a rod that accelerated 
continuously during 300 s from 0 to 50 rpm. The latency 
between each trial run was at least 40 s. This paradigm was 
designed in a way that all mice fell from the rod at some time 
point [45]. The average time on the rotarod and the best per-
formance out of three runs were evaluated. If in a run an ani-
mal fell of the rod immediately (i.e., did not stay on the accel-
erating rod for more than 10 s), this run was repeated. Up to a 
maximum of three repeats per test day were conducted.
For all mice, rotarod performance was normalized to their 
mean performance between 42 and 51 weeks of age. As cut-
off to assess the start of neurological symptoms, we used 
the normalized mean rotarod performance of age-matched 
non-tg mice at the age of 42–51 weeks minus three sigma 
(=55.28). Mice with the best run below this value were con-
sidered symptomatic. Animals that were not able to stay at 
least once for more than 20 s on the accelerating rotarod 
on the test day were considered terminally ill and sacri-
ficed. In addition, four animals matched in regard to sex 
and litter were sacrificed per experimental group at the age 
of 69 weeks for analysis of pre-terminal histopathological 
changes. Fluctuations in rotarod performance in the prodro-
mal stage were determined by assessing the standard devia-
tion of the best rotarod performance in the measurements 
between 300 and 450 days of life for individual animals.
All animals were submitted to pathological examination. 
For histopathological and immunohistochemical investi-
gation, formalin-fixed brain tissue was used. Pathological 
deposits of human α-syn were detected by the anti-human-
α-syn antibody 15G7 [47]. In detail, 1-μm tissue slices were 
deparaffinized, treated with 0.2 M boric acid, pH 9 at 63 °C 
for 25 min and afterwards stored in the same buffer for 30 min 
at room temperature. Then the slices were washed with Mil-
lipore water and stained with haemalum. For PK digestion 
50 mg/ml PK stock solution was diluted 1/500 with digestion-
buffer (10 mM Tris–HCl, pH 7.8 + 100 mM NaCl + 0.1 % 
BRIJ35). PK digestion was performed for 10 min at 37 °C. 
After washing, the slices were treated for 32 min with 15G7 
in 1/4,000 dilution and then with a biotinylated rabbit anti-
rat secondary antibody (Dako, Hamburg, Germany) at 1/300 
dilution for 20 min. DAB was used for detection.
Continuous sucrose-gradient assay
Continuous sucrose-gradient assay was performed as 
described by Tzaban et al. [63] with minor modifications. 
Briefly, 10 % brain homogenates (w/v) were prepared using 
1× PBS (pH 7.2) containing 0.1 % NP-40 with protease 
inhibitor cocktail EDTA-free (Roche, Switzerland) and 
were stored at −80 °C without centrifugation. Before fur-
ther processing, samples were thawed on ice. To obtain a 
1 % (w/v) brain homogenate 1× PBS containing 0.5 % 
sodium deoxycholate and 1 % sarcosyl was added. Then 
samples were agitated with 1,200 rpm at 4 °C for 30 min 
(Thermomixer Comfort, Eppendorf, Germany). To discard 
debris, samples were centrifuged with 20,000g at 4 °C for 
1 min. To prepare a sucrose-gradient solutions containing 
10 mM Tris (pH 7.2), 1 % sarcosyl and sucrose (10, 20, 
30, 40, 50 and 60 %, respectively) were filled into a 4-ml 
11 × 60 mm polyallomer tube (Beckman coulter, USA) 
beginning with 200 μl of 60 % sucrose solution loaded to 
the bottom, then followed by 400 μl of 50–10 % sucrose. 
Finally, 200-μl brain homogenate was loaded on the top of 
the sucrose-gradient. Ultracentrifugation with 100,000g at 
4 °C for 1 h was performed using a Sw60Ti rotor (Beck-
man coulter, USA). Samples for western blotting were 
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harvested after centrifugation from the top to the bottom of 
the sucrose-gradient in 200 μl fractions (i.e. fraction 1 rep-
resents the top of the gradient and fraction 12 the bottom 
fraction). For RML samples, fractions from the sucrose-
gradient were digested with 50 μg/ml PK at 37 °C for 1 h. 
The reaction was stopped by adding 2× loading buffer 
and boiling at 100 °C for 15 min. Synuclein fractions were 
boiled in 2× loading buffer for western blotting.
Anle138b fluorecence measurement
Fluorescence measurements of anle138b in combination 
with α-syn monomers and fibrils were performed in fused 
silica cells (Hellma, 10 × 4 mm, Typ 117.104F-QS) with 
a spectrofluorometer (Horiba, Fluorolog3) in front-face 
geometry. A solution of 250 nM anle138b in buffer con-
taining 0.0025 % (v/v) DMSO was prepared by adding 
2.5 μl of a 10-mM anle138b solution in DMSO to 100 ml 
of 50 mM Tris-buffer (pH 7.0) under ultra sound treatment 
at about 30 °C. Two identical cells, Cell1 and Cell2, were 
filled with this 250-nM anle138b solution and fluorescence 
spectra (excitation at 300 nm, 2 μW) were recorded. At the 
excitation wavelength, the absorption of the sample is domi-
nated by anle138b. Subsequently, about every 30-min small 
amounts of 50-μM monomeric α-syn and 13-μM aggre-
gated α-syn were added to Cell 1 and Cell 2, respectively, 
and fluorescence spectra were recorded. Both cells were 
stirred during the fluorescence measurements. For aggrega-
tion, 50 μM α-syn in 50 mM Tris–HCl, pH = 7.0 containing 
100 mM NaCl and 0.02 % of NaN3 was incubated for 96 h at 
37 °C under constant agitation (1,400 rpm). Directly prior to 
the fluorescence measurements this solution was centrifuged 
(15 min, 10,000 rpm) to remove residual monomeric α-syn. 
The pellet was resuspended in Tris–HCl, pH = 7.0 and a 
solution of 13 μM of α-syn in the aggregated form (concen-
tration determined by Tyrosin absorbance at 280 nm) was 
obtained. At 300 nm absorption and corresponding emission 
from the tyrosines in α-syn is small. In order to consider 
this contribution we performed reference measurements 
by adding the monomers and fibrils to cells containing the 
same buffer (Tris-buffer (pH 7.0), 0.0025 % (v/v) DMSO) 
but no anle138b. The emission recorded from these samples 
was subtracted from the emission recorded in the original 
experiment.
Results
Discovery of anle138b and related DPP compounds  
by screening for anti-prion compounds
We tested a compound collection of 20,000 chemically 
diverse drug-like compounds both for inhibition of prion 
protein aggregation using a molecular SIFT assay [2, 3] 
and in an anti-prion cell culture assay [25, 41]. Structure–
activity and cluster analysis of the data obtained with these 
two independent high-throughput screening approaches 
identified a cluster of highly active compounds belonging to 
the chemical class of 3,5-diphenyl-pyrazole (DPP) deriva-
tives (Suppl. Fig. 1). Therefore, we synthesized a focussed 
library of ~150 DPP-related compounds and tested these 
compounds in vitro for inhibition of pathological prion and 
α-syn oligomer formation, in cell culture, and in vivo for 
therapeutic effects on disease progression and oligomer 
formation in a range of animal models. A detailed account 
of our experimental drug discovery strategy is provided in 
Fig. 1.
Evaluation of the DPP lead structure according to medic-
inal chemistry criteria [12, 42, 64] indicated good metabolic 
stability and oral bioavailability required for long-term ther-
apy. First in vivo experiments were done in the prion model, 
as this provides an authentic neurodegenerative disease 
model with a well-defined and relatively rapid time course. 
Compounds were given orally and, in addition to thera-
peutic efficacy, brain levels were investigated for a number 
of compounds (Table 1). In these experiments, anle138b 
[3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyra-
zole] showed the highest anti-prion activity both in vivo and 
in vitro (Fig. 2). Comparison of anle138b with systematic 
variations of this structure revealed a well-defined struc-
ture–activity relationship (SAR). Regarding the 5-phenyl 
(R3), bromine in meta-position led to the highest inhibitory 
activity, whereas the change of bromine location to para- or 
ortho-position in the 5-phenyl ring (R3) reduced or abol-
ished the activity, respectively. Interestingly, substitution in 
the ortho-position for steric reasons tilts this phenyl ring so 
that the molecule is no longer planar (Suppl. Fig. 4). Testing 
different halogen atoms in the meta-position revealed a bell-
shaped correlation with the size of the substituent. Regard-
ing the central five-membered ring (R2), pyrazole was 
associated with highest activity. For the substituent at the 
3-phenyl (R1), SAR was more complex, as modifications 
in this position strongly affected bioavailability in the brain. 
1,3-Benzodioxole as in anle138b was associated with best 
bioavailability and good inhibitory activity in vitro, thus 
resulting in highest activity in vivo. Notably, when brain 
levels are taken into account, there is a strong correlation 
between anti-prion activity in vitro and in vivo (Fig. 2) indi-
cating that the therapeutic effect in vivo is based on direct 
targeting of PrPSc.
Efficacy of treatment started after onset of disease
SAR was primarily investigated through the effect of treatment 
for 40 days [80–120 days post infection (dpi)] on PrPSc accu-
mulation, which provides a rapid and reliable biochemical 
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quantification and thus allowed testing of a large number of 
compounds in vivo. To further investigate the mode of action 
and therapeutic potency, we chose anle138b, which in our 
SAR study had the highest therapeutic efficacy in vivo. To 
be useful for treatment in humans, a compound should also 
be effective when given after signs and symptoms of disease 
are detectable. Thus, we analyzed the effect on clinical out-
come (i.e. motor performance, weight loss and survival) for 
treatment started at different time points after intracerebral 
infection (Fig. 3; Suppl. Fig. 5). Without treatment, at about 
80 dpi subtle clinical signs can be observed [44] and PrPSc 
is detectable in the brain (Fig. 3c), at 120 dpi obvious signs 
Table 1  Structure–activity relationship for various DPP-derivatives







anle138b 77 84 78
a; 57b,
108c 34.1
sery312b <10 42 13a 3,6
anle253b 50 80 59a 2.1
sery384 99 55 <10a 13,9
sery417 <10 51 <10a 0
anle138c 99 19 <10a n.d.
sery338b <10 46 35a 30.3
sery345 57 <10 <10a 16.6
sery378b 74 34 39a 26
anle234b <10 <10 <10a 32.1
anle186b <10 48 30c 31.1
sery335b 90 52 68a; 46b 29.6
anle197b <10 16 <10b n.d.
anle236b <10 <10 12a 39.3



































The table summarizes the effect of various compounds in regard to α-syn oligomer formation and prion propagation in vitro (SIFT, PMCA) and 
in vivo in prion-infected mice, as well as compound concentrations achieved in the brain 4 h after oral application of 1 mg compound in DMSO/
peanut butter. For all compounds other than anle138b, only the part of the molecule (R1, R2, or R3) that differs from this lead structure is dis-
played
$
 Inhibition relative to high control, 10 μM compound, 1 % DMSO, 10 μM FeCl3
#
 Inhibition relative to high control, 10 μM compound, RML prion strain
* Relative inhibition of PrPSc  accumulation normalized to DMSO-treated group (0 % inhibition) and PrPSc level at start of treatment (100 % 
inhibition)
a
 PrPSc level in brain 120 days after i.c. infection and treatment for 40 days with 1 mg compound (oral, in peanut butter)
b
 PrPSc level in spleen determined 35 days after i.p. infection followed by 34 days of treatment with 1 mg compound (oral, in peanut butter)
c
 PrPSc level in brain at 106 days after i.c. infection and treatment for 24 days [14 days i.p. (0.84 mg compound); 2 × 5 days oral by gavage 
(1 mg)]
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of disease are present (Fig. 3b, c). Even start of treatment 
with anle138b after onset of disease at 120 dpi resulted in 
a substantially prolonged survival and preservation of body 
weight (Fig. 3a, b; Suppl. Fig. 6). To our knowledge, the pro-
longation of survival obtained with anle138b is the largest 
that has been found for any drug-like compound tested so 
far in late-stage treatment experiments [15, 17, 36, 62]. The 
medicinal chemistry optimization of DPP compounds thus 
was essential for high in vivo efficacy compared to the effi-
cacy observed for the first hit compounds derived from the 
compound collection used for primary screening [25, 41].
Analysis of mice at different time points during treatment 
revealed that anle138b strongly inhibited accumulation of 
PrPSc (Fig. 3c, d) and neuronal cell death (Fig. 3e) even 
when start of treatment was in the symptomatic phase. Inter-
estingly, the number of pyknotic nuclei indicating apoptotic 
neuronal cell death seemed not to depend on the absolute 
amount of PrPSc but correlated with the rate of PrPSc ampli-
fication. This is in line with published data [13] and pro-
vides an explanation for the strong therapeutic effect found 
also in the late-treatment group.
Targeting of pathological protein aggregation by anle138b
Regarding mode of action, these findings in combina-
tion with the finding that PrPC expression is unaffected by 
anle138b (Suppl. Fig. 7) indicate that anle138b directly 
blocks PrPSc amplification and reduces neurotoxicity in 
vivo. Notably, we observed a significant change in size 
distribution of aggregates indicating a modulation of the 
abundance of different oligomeric species. To characterize 
oligomer formation in vivo, we used sucrose-gradient cen-
trifugation, as this method, which is well established in the 
prion field [52], has several advantages compared to other 
methods for analysis of size distribution of aggregates: (i) it 
allows direct analysis of brain homogenates, which would 
be difficult by gel filtration, (ii) there is no purification 
step, which might modify the aggregation state, required 
prior to analysis, and (iii) it allows to detect and quantify 
all potential particle sizes (i.e. monomers, oligomers, fibrils) 
simultaneously. Analysis of brain homogenates by sucrose-
gradient centrifugation assay reveals a strong reduction 
of high molecular weight species and also a shift towards 
smaller oligomer size for low molecular weight oligom-
ers (Fig. 4a, b). That oligomer modulation—in addition to 
reduced toxicity—also interferes with PrPSc amplification is 
further corroborated by the fact that PrPSc amplification is 
also blocked in a cell-free in vitro protein misfolding cyclic 
amplification (PMCA) assay (Fig. 4c, d; Suppl. Fig. 8). This 
method provides several key advantages for compound test-
ing. It has been shown that PMCA provides an experimental 
tool for rapid propagation of authentic infectious prions in 
vitro [67] and preserves strain properties [10]. Importantly, 
this approach constitutes the only experimental approach to 
test the efficacy of compounds in a purely human system 
(human prions + human brain tissue). Moreover, we found 
that the results obtained in the PMCA assay are predictive 
for the effects observed in vivo (Table 1; Fig. 2). We tested 
anle138b using a range of murine (RML, ME7 and 301C i.e. 
mouse-adapted BSE) and human strains (sCJD and vCJD). 
Anle138b strongly inhibited all prion strains tested includ-
ing BSE-derived and human prions in a purely human sys-
tem. Dose–response curves for the RML prion strain used 
in our animal experiments and for human vCJD were simi-
lar (EC50RML = 7.3 μM, EC50vCJD = 7.1 μM), indicat-
ing that this compound may also be useful for treatment of 
human prion disease (Suppl. Fig. 8).
Pharmacokinetic analysis
Pharmacokinetic (PK) analysis of the different application 
protocols used in mice modelling CJD as well as Parkinson’s 
disease (vide infra) revealed that anle138b has an excellent 
oral bioavailability and excellent blood–brain-barrier pen-
etration, and that concentrations shown to be active in the 
PMCA assay were obtained in the brain (Fig. 5). Key find-
ings in regard to PK are that (i) oral application of anle138b 
consistently results in approximately 50 % of the AUC (area 
under the curve) values compared to i.p. application, which 
indicates very good oral bioavailability, (ii) application in 
Fig. 2  Correlation between anti-prion activity in vitro and in vivo. 
For compounds shown in Table 1 that reach brain levels ≥15 nmol/g 
(indicated by dark blue dots), there is a strong linear correlation 
(R = 0.951) between anti-prion activity in vitro and in vivo. Those 
compounds that reach lower brain levels (light blue dots) result in 
lower in vivo activities. No compounds with low anti-prion activity 
in the PMCA assay in vitro are active in vivo. Anle138b is the most 
active compound in both assays. Anti-prion activity is provided as % 
inhibition
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peanut butter results in slower resorption and prolonged 
availability of anle138b, (iii) a higher dose results in a pro-
portional increase in serum and brain levels indicating lin-
ear PK without saturation of clearance, and (iv) at all time 
points in all experimental groups anle138b reaches ~3-fold 
higher levels in the brain than in the serum, which cor-
roborates excellent blood–brain-barrier penetration. Thus, 
anle138b has a better bioavailability compared to several 
potential anti-aggregation drugs investigated previously, for 
which concentrations in the brain were found to be low [56]. 
Dose–response analysis for the effect of anle138b in vivo 
(Suppl. Fig. 9) is compatible with pharmacokinetic data and 
the dose–response curves obtained in vitro. In some experi-
ments, even a reduction of PrPSc levels could be obtained 
with anle138b (Suppl. Fig. 10). At the same time, investiga-
tion of the brain extracts with HPLC in combination with 
high resolution mass spectroscopy did not identify metabo-
lites of anle138b (Suppl. Fig. 11) in the brain, indicating that 
anle138b is most probably the active oligomer-modulating 
molecule.
Fig. 3  Influence of daily anle138b treatment on PrPSc accumulation 
and prion pathology of mice infected with RML scrapie. a Survival 
curves of mice treated orally with anle138b beginning at 0, 80 or 
120 days post i.c. prion infection. Treatment resulted in prolonged 
survival, even when started at an advanced disease stage at 120 dpi. 
For detailed statistics see Suppl. Fig. 6, n = 7–9. b Control mice 
showed progressive weight loss starting after 100 dpi. Treatment with 
anle138b from 80 dpi onwards prevents weight loss for ~100 days. 
Treatment from 120 dpi inhibits further weight loss for ~70 days. c 
Immunohistochemistry (upper row cortex/hippocampus, middle row 
cerebellum) and dot blot analysis (lower row) showed that anle138b 
treatment inhibits PrPSc accumulation in comparison to DMSO-
treated control animals. d Quantification of brain PrPSc levels at dif-
ferent time points shows highly significant inhibition of PrPSc accu-
mulation in mice treated from 80 dpi onwards. PrPSc accumulation is 
also reduced in animals treated from 120 dpi. e Histological analy-
sis reveals a significantly reduced number of pyknotic nuclei both in 
mice treated from 80 and 120 dpi onwards. Inset shows an example 
of a pyknotic granule cell nucleus (arrow). Error bars in (d) and (e) 
indicate standard error (n = 4), **p < 0.01, ***p < 0.001. The legend 
shown in (a) also applies to (b–e)
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Efficacy of anle138b in synucleinopathies
α-Synucleinopathies share molecular features in regard to 
aggregate structure and seeding with prion diseases [1, 29, 
43] and are of high clinical importance due to their high 
prevalence [19]. Thus, we tested our library of DPP-deriv-
atives with respect to effects on α-syn oligomer formation 
and found several active compounds (Suppl. Fig. 12), as 
well as several parallels with the anti-prion effect regarding 
SAR (Table 1). Again, at R3 the type and position of the hal-
ogen substituent was crucial with a complete block of activ-
ity with bromine in the ortho-position, and again pyrazol 
was the most active variant at R2. Anle138b turned out to 
inhibit α-syn oligomer formation at the same concentration 
range that was active in the PMCA anti-prion assay (Fig. 6a, 
Suppl. Fig. 13) and that was reached in brain tissue (Fig. 5). 
Moreover, we could show in vitro that anle138b also inhib-
ited generation of pathological α-syn oligomers that formed 
ion-permeable pores in lipid membranes, a potentially neu-
rotoxic effector species in α-syn-related neurodegenerative 
diseases [11, 38, 40, 55] (Fig. 6b).
Recent evidence suggests that α-syn aggregation also 
plays a role in mediating toxicity of complex-I inhibitors 
[9, 21, 48]. In order to test the neuroprotective effect of 
anle138b in vivo, we used a recently established low-dose 
oral rotenone model that recapitulates essential features of 
PD pathology in humans such as α-syn accumulation and 
progressive spread of pathology [18, 48]. Due to the low 
dose and intragastric application of rotenone, the direct 
toxic effect of rotenone is confined to the gut without sys-
temic complex-I inhibition in the brain and muscles, thus 
differing from classical rotenone models. In oral rotenone-
treated mice, α-syn pathology propagates from the enteric 
nervous system to the CNS through synaptically con-
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Fig. 4  Size modulation of PrPSc oligomers by anle138b and inhibi-
tion of various human and non-human prion strains in PMCA. (a, b) 
Size distribution of PrPSc aggregates was analyzed by sucrose-gradi-
ent centrifugation. Mice treated with anle138b show a strong reduc-
tion of high molecular weight species (fractions 7–12). Also small 
molecular weight oligomers (fractions 3–4) are reduced and show a 
shift towards smaller size (fraction 2) indicating that anle138b blocks 
aggregation at the level of small oligomers. DMSO-treated mice are 
indistinguishable from terminally ill untreated mice. (c, d) For PMCA 
assay, infected brain homogenates were diluted 100-fold by appro-
priate normal brain homogenates containing compounds (1 μl of 
10 mM solutions in DMSO) or 1 μl of DMSO as control. c Mouse-
adapted scrapie strains (RML, ME7) and Mouse-adapted BSE (301C) 
were used as seed in C57/BL6 mouse normal brain homogenates. 
d sCJD and vCJD samples were propagated in non-CJD human brain 
homogenates. In all gels, 0.5 % (w/v) normal brain homogenates 
from C57/BL6 and human brain, respectively, were loaded directly in 
the last lane without proteolysis as a reference (indicated as PrPC on 
the top). All other samples were treated with 50 μg/ml PK. “Start” 
(lane 1 of each gel) indicates samples containing infected brain 
homogenate before PMCA. Molecular weight markers are indicated 
on the right. PrP migrates in three different bands due to the presence 
of non-glycosylated, mono-glycosylated, and di-glycosylated forms, 
and digestion with Proteinase K results in a shift to lower molecu-
lar weights with the non-glycosylated band migrating at ~20 kD. 
Anle138b shows a strong inhibitory activity in all prion strains tested. 
As an additional control, the inactive isomer anle234b (see Table 1, 
Suppl. Fig. 4) was used. Quantitative PMCA results are provided in 
Table 1 and Suppl. Fig. 8
▸
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Fig. 5  Pharmacokinetic analysis of anle138b. (a, b) A single dose 
of anle138b was applied to non-infected C57/BL6 mice as indicated 
in the figure legends. In detail, intraperitoneal application was per-
formed using 1 mg compound in 25 μl DMSO, oral application by 
gavage was done with 1 mg compound in 10 μl DMSO + 40 μl veg-
etable oil, and oral application of 1 mg as well as 5 mg compound 
in peanut butter was done by providing the compound dissolved in 
10 μl DMSO mixed with 200 μl peanut butter. At different time 
points after application (0.5, 1, 2, 4, 8, and 24 h) two animals per 
group and time point were sacrificed and the amount of compound 
in the serum (a) and brain (b) was measured by LC-MSMS. c From 
the results obtained following i.p. application, half-life of anle138b 
in serum and brain was calculated. d Calculation of AUC values. To 
facilitate comparison with the groups receiving a dose of 1 mg, for 
the group receiving 5 mg anle138b (green columns) we also provide 
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Fig. 6  Effect of anle138b on α-syn oligomer formation. a Iron-
induced oligomer formation of α-syn analyzed by SIFT assay [38] 
is blocked by anle138b in a dose-dependent manner, the apparent 
EC50 is 2.8 μM. Error bars indicate standard error. b Pore forma-
tion in lipid bilayers by α-syn oligomers is significantly reduced in 
presence of 25 μM anle138b. Similar results are obtained for 50 μM 
baicalein. Raw data for panels a and b are shown in Suppl. Fig. 13. 
For statistical analysis, we used student’s t test (a) and Fisher exact 
test (b). Statistical significance is indicated by *p < 0.05; **p < 0.01; 
***p < 0.001
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to transsynaptic spread and that α-syn aggregation induces 
dopaminergic cell death and the resulting motor phenotype. 
Interestingly, anle138b prevented the development of motor 
dysfunction in this synucleinopathy/PD model [48] to the 
same extent as hemivagotomy. This surgical procedure has 
recently been shown to partially block the spread of α-syn 
pathology from the enteric nervous system to the CNS [49] 
(Fig. 7a). Moreover, treatment with anle138b almost com-
pletely rescued the phenotype in the 1-h stool collection gut 
motility test (Fig. 7b), which has previously been shown to 
correlate with the presence of α-syn pathology in the enteric 
nervous system in this model [49].
In a further set of in vivo experiments, treatment with 
anle138b also blocked dopaminergic cell death in the substan-
tia nigra in a sub-acute MPTP mouse model for PD (Suppl. 
Fig. 14). However, the details of the interaction between 
mitochondrial toxins, progression of pathology, and α-syn 
aggregation are not fully established. Thus, we also tested the 
effect of anle138b in a well-established long-term transgenic 
α-synucleinopathy mouse model based on neuronal expression 
of human A30P-α-syn [47] (Fig. 8). In placebo-treated trans-
genic mice, pathological deposition of α-syn in the brain was 
first detected in the brain stem at the end of the first year of 
life, increased with time and spread to supratentorial areas. 
Signs of disease developed in parallel to α-syn deposition. 
During a prodromal phase (approximately 300–450 days of 
age), rotarod measurements revealed increased fluctuations 
in motor performance (Fig. 8a), which are a typical feature 
of human synucleinopathies [61]. In addition, reduced gain 
of weight was observed (Fig. 8b). This was followed by a 
clinical phase characterized by a rapid decline in rotarod 
performance. Anle138b significantly reduced fluctuations in 
motor performance approaching the level of non-transgenic 
control mice (Fig. 8a) and lead to an almost normal increase 
in body weight as observed for wt mice (Fig. 8b). Disease-
free survival was prolonged significantly (p < 0.05) by 
~10 weeks (Fig. 8c). In anle138b-treated mice, we observed 
that pathological deposition of α-syn in the brain was reduced 
(Fig. 8d; Suppl. Fig. 15). Similar to the prion mouse model, 
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Fig. 7  Effect of anle138b in animal models of Parkinson’s disease: 
low-dose intragastric rotenone model. a A significant decrease in 
motor performance (Rotarod) can be observed in rotenone-treated 
mice (normal feed and placebo feed) compared to the non rotenone-
treated control group both after 3 (p < 0.01) and 4 (p < 0.001) months 
of rotenone treatment. This effect is ameliorated by treatment with 
anle138b. Both anle138b and hemivagotomized mice present a signif-
icantly improved motor performance after 3 (p < 0.01) and 4 months 
(p < 0.01) when compared to rotenone-treated (normal feed and pla-
cebo feed) mice. Interestingly, no significant differences (p > 0.20) 
could be observed between hemivagotomized or anle138b rotenone-
treated mice at any time point, indicating an effect size of anle138b 
similar to the hemivagotomy which has recently been shown to 
partially block the spread of α-syn pathology from the enteric nerv-
ous system to the CNS [49]. b 1-h stool collection gut motility test. 
Decreases in stool deposition have been previously shown to correlate 
with the presence of α-syn pathology in the enteric nervous system 
as a result of rotenone treatment. Co-treatment with anle138b results 
in a complete rescue of enteric function. Whereas all rotenone-treated 
mice (including hemivagotomized mice) present significant altera-
tions (p < 0.05) in stool deposition, anle138b-rotenone-treated mice 
show no significant difference in stool deposition when compared to 
controls. Error bars in (a, b) indicate standard error. For statistical 
analysis 2-way ANOVA with Bonferroni post hoc test was used
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in the anle138b-treated mice (Fig. 8e, f; Suppl. Fig. 16). The 
level of total α-syn was unchanged in anle138b-treated mice 
(Suppl. Fig. 17), indicating that anle138b does not interfere 
with expression and degradation of α-syn in these mice but 
acts as an aggregation inhibitor. Notably, no toxic effect of 
anle138b was observed in our in vivo experiments even after 
long-term high-dose treatment.
In preparation for a first clinical trial, preclinical assays 
for acute toxicity and mutagenicity yielded promising results 
(Suppl. Fig. 18). However, further preclinical safety studies 
will be required prior to clinical studies in humans. Anle138b 
does not interfere with the formation of physiological fibrillar 
protein assemblies that are structurally different from amy-
loid such as actin as shown by in vitro experiments (Suppl. 
Fig. 19). Such an interaction was not expected given the treat-
ment of mice for more than a year without any sign of toxicity.
Binding studies using intrinsic fluorescence of anle138b
Based on the molecular structure of anle138b, we considered 
the possibility that this compound has an intrinsic fluorescence 
that might be employed for direct molecular binding studies. 
We found that in aqueous solution with excitation at 300 nm, 
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Fig. 8  Effect of anle138b in animal models of Parkinson’s disease: 
A30P-hum-α-syn transgenic mice. Effect of treatment with anle138b 
in a transgenic mouse Parkinson model based on neuronal overex-
pression of A30P-hum-α-syn [47]. a In the prodromal phase of the 
disease (300–450 days of age), placebo-treated transgenic animals 
exhibit significantly increased fluctuations in rotarod performance. 
This phenotype can be rescued by treatment with anle138b. b In 
this time span, nearly normal development of body weight can be 
observed in the anle138b treated group, whereas the placebo-treated 
group shows reduced gain of weight. Mouse weights were normal-
ized to the mean weights obtained at measurements between 250 
and 315 days of age. c Kaplan–Meier evaluation of treatment with 
anle138b shows a significant increase in disease-free survival. The 
median disease-free survival is prolonged by 10 weeks. d Representa-
tive sections from the brain stem show a reduction of pathological 
α-syn deposits in 69-week-old anle138-treated mice in comparison 
to placebo-treated age- and sex-matched littermates (see also Suppl. 
Fig. 15). (e, f) Sucrose-gradient centrifugation shows that in young 
transgenic mice α-syn is found in the same fractions (1–2) as mono-
meric recombinant α-syn. In 69-week-old placebo-treated mice, α-
syn oligomers can be found that show the same size distribution as 
oligomers derived from recombinant α-syn by treatment with DMSO/
Fe3+. Oligomer formation in transgenic mice is inhibited by treatment 
with anle138b. For the corresponding graph shown in (f), four mice 
per group were analyzed (Suppl. Fig. 16). Error bars in (a, b, f) indi-
cate standard error. For statistical analysis, we used student’s t test, 
Statistical significance is indicated by **p < 0.01 (a), log-rank test 
(Mantel-Cox) and Gehan-Breslow-Wilcoxon test (c), and ANOVA 
and multiple comparison post-test (f)
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but exhibits a very weak intrinsic fluorescence (Fig. 9). The 
fluorescence properties of anle138b do not change upon addi-
tion of monomeric α-syn. However, one observes a strong 
increase in the fluorescence intensity of anle138b by more 
than a factor of 30 when pre-aggregated α-syn was added, 
indicating strong structure-dependent binding of anle138b to 
aggregated α-syn even at nanomolar concentrations (Fig. 9b).
Discussion
Regarding treatment of neurodegenerative diseases in 
humans, DPP-derivatives and specifically anle138b repre-
sent a new lead structure with several favourable features. 
They are small molecules that have an excellent oral bioa-
vailability and blood–brain-barrier penetration without signs 
of toxicity at therapeutic doses. To the best of our knowl-
edge, the prolongation of survival even in late-stage treat-
ment experiments obtained in prion-infected mice is by far 
the largest that has been found for any drug-like compound 
tested so far (Suppl. Fig. 20). We found that anle138b has 
several beneficial properties compared to previously identi-
fied molecules such as compound B by Kawasaki et al. [36]: 
(i) the effect on survival is larger, (ii) anle138b has better 
pharmacokinetic properties (e.g. a longer half-life), and (iii) 
compound B was reported to lack activity for certain prion 
strains and—at the biochemical level—to be less efficient 
for double glycosylated PrPSc species, whereas we show 
that anle138b is active in all strains tested (including human 
CJD and BSE-derived strains) and that there is no lack of 
activity for double glycosylated PrPSc. We did not observe 
a selection and over-representation of this PrPSc species in 
treated animals (Fig. 4a). Several studies aiming at the devel-
opment of new therapeutic anti-prion compounds showed 
anti-prion activity only in cell culture but either lacked data 
from animal models or were found to be inefficient in vivo 
[23, 26, 60]. For example, quinacrine was reported to exhibit 
a high anti-prion activity in cell culture [37]. However, in 
vivo studies in mice and humans were unsuccessful [14] as 
this compound does not reach sufficient concentrations in the 
brain [24], which underlines the importance of systematic 
and timely in vivo testing to optimize therapeutic efficacy of 
synthesized compounds not only in vitro but in vivo.
Regarding the mode of action of anle138b, we present 
comprehensive evidence, that it is based on direct modula-
tion of aggregation at the oligomer level. At the molecular 
level, we demonstrate that anle138b blocks the formation 
of toxic pore-forming α-syn oligomers (Fig. 6) for which 
we previously provided a detailed morphological and struc-
tural characterization based on single-particle spectroscopy 
and atomic force microscopy [38], as well as single-channel 
electrophysiology [55]. It has been shown that these glob-
ular oligomers are able to interact with lipid membranes, 
form pores, modulate electrophysiological properties of 
neuronal cells and cause toxicity in cell culture [32, 33, 38, 
55]. In vivo, we see a diversion of formation of disease-
associated oligomers to smaller oligomers and monomers 
by anle138b treatment for both PrPSc and α-syn (Figs. 4a, 
b; 8e, f). Importantly, anle138b does not lower the level 
of normal PrPC and α-syn (Suppl. Fig. 7; Suppl. Fig. 17), 
which indicates that this compound directly interferes with 
pathological aggregation. This is further corroborated by 
the anti-aggregative activity of anle138b in vitro both in 
regard to α-syn aggregation and in regard to prion propa-
gation in cell-free assays. Notably, the anti-aggregative 
activity in vitro and the reduction of aggregated species in 
vivo correlate well with the therapeutic effect in vivo for all 
compounds tested (Fig. 2). In addition, we show a direct 
and structure-dependent binding, i.e. a direct targeting of 
pathological aggregates by anle138b, based on a dramatic 
change in intrinsic fluorescence, whereas there is no indica-
tion for binding to monomers (Fig. 9).
Fig. 9  Structure-dependent binding of anle138b. Intrinsic Fluores-
cence of 250nM anle138b was measured with excitation at 300 nm. a 
Addition of α-syn monomers does not significantly change the weak 
fluorescence of anle138b. b Addition of pre-aggregated α-syn results 
in a dramatic change in the fluorescence properties with a strong 
increase of fluorescence at ~340 nm by more than a factor of 30. This 
points to specific binding of anle138b to a structure-dependent bind-
ing site
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Thus, our findings indicate that the therapeutic effect in 
vivo is due to direct targeting of pathological aggregation 
at the level of oligomers and not to indirect effects such as 
reduced protein expression or increased clearance. However, 
the identification of residues with which anle138b interacts 
on α-syn and prion protein oligomers is so far unsolved. This 
is due to fundamental experimental challenges which are:
1. Unlike some other compounds, anle138b does not bind 
to the monomer (Fig. 9). From a therapeutic view this 
is a major advantage, as anle138b is therefore unlikely 
to interfere with the physiological functions of the non-
aggregated protein. For monomer binders such as PcTS, 
NMR was successful in localizing the residues where 
the interaction occurs [39]. Since oligomers are a very 
mobile and dynamic assembly of monomers which are 
partially unstructured, NMR-based approaches failed 
so far to identify the residues which interact with small 
molecule inhibitors such as anle138b.
2. Anle138b is soluble in water only in concentrations 
below 1 μM precluding high-resolution NMR spectros-
copy of complexes of anle138b with soluble oligomers.
3. As anle138b binds to a structure-dependent epitope, it 
may well be that the compound interacts with several 
residues, which would require a full structure deter-
mination of the oligomer to characterize the binding 
epitope. However, atomic resolution oligomer struc-
tures are not available neither in solution nor in the 
membrane. Fibrils are much more structured and this 
allowed for the only work available so far, namely the 
residue-specific atomic resolution structure of congo-
red with het-S fibrils. Unlike oligomers, these fibrils 
are very well structured and stable [66].
The fact that the atomic resolution structure of prions, 
pathological oligomers, and amyloid fibrils remains to be 
elucidated constitutes a major challenge for drug develop-
ment for neurodegenerative diseases and may be one key 
reason that there are no drugs available for treatment of 
human patients so far. Therefore, some groups work on 
compounds that bind to and stabilize the conformation of the 
physiological conformation of aggregation-prone proteins. 
This approach has been successful in the case of the tar-
get transthyretin [16] which is a folded protein with known 
atomic resolution structure. The mode of action of these 
compounds is fundamentally different from our approach, 
which targets the aggregated state. Importantly, inhibition of 
the aggregation of intrinsically unfolded proteins like in the 
case of α-syn cannot use this strategy. Thus, we employed 
an innovative approach to drug development. We performed 
molecular screening using SIFT, a novel method based on 
single-particle spectroscopy that allows targeting oligomer 
formation. Due to the low concentration of α-syn used in 
this assay, solubility requirements for the compounds did 
not bias dramatically against lipophilic compounds. This 
method was a key success factor for finding anle138b, since 
it represents the first described way to target intrinsically 
disordered proteins. Moreover, the use of prion-infected 
mice allowed efficient testing of a large number of com-
pounds in vivo in an authentic disease model and, thus, to 
optimize compounds in regard to in vivo efficacy while bal-
ancing the in vitro efficacy in an unprecedented way.
In summary, our experiments show that targeting protein 
oligomers provides a potent disease-modifying therapy in 
vivo for both prion diseases and PD, and corroborate the key 
role of protein oligomers in disease pathogenesis. In addi-
tion, anle138b provides a new tool to further dissect the role 
of protein aggregates during disease pathogenesis in vivo. 
The finding that DPP compounds modulate the formation of 
pathological oligomers of both prion and α-syn and inhibit 
disease progression with obvious parallels regarding SAR 
fits well with recent evidence that pathological aggregates 
in these diseases share common structural features and have 
similar properties with respect to binding of specific struc-
ture-sensitive antibodies and certain chemical dyes such 
as congo-red and thioflavinT [29, 58]. This suggests that 
common basic principles regarding the structure of toxic 
aggregates are involved in these diseases and amenable to 
pharmacological inhibition in vivo.
So far, no drug using this molecular mode of action has 
entered clinical practice. Current therapies for neurodegen-
erative diseases such as Alzheimer’s disease, Parkinson’s 
disease and prion diseases target disease symptoms [20]. 
Here, we show that compounds targeting oligomer formation 
can have a broad spectrum of activity in the treatment of dif-
ferent protein aggregation diseases. Therefore, we currently 
extend our experiments with anle138b to Abeta, tau, SOD1 
and TDP43 aggregation important for AD, frontotemporal 
dementia (FTD), and amyotrophic lateral sclerosis (ALS).
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